首页> 外文期刊>海南医科大学学报(英文版) >Mechanism research of pirarubicin postoperative immediately bladder irrigation combined compound matrine injection on treating superficial bladder cancer
【24h】

Mechanism research of pirarubicin postoperative immediately bladder irrigation combined compound matrine injection on treating superficial bladder cancer

机译:吡柔比星术后即时膀胱冲洗联合复方苦参碱注射液治疗浅表性膀胱癌的机制研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:Investigate the mechanism of Pirarubicin postoperative immediately bladder irrigation combined compound matrine injection on treating superficial bladder cancer, thus to provide assistance for clinical therapy of superficial bladder cancer.Methods:A total of 90 cases of patients with superficial bladder cancer treated in our hospital were selected, and randomly divided to be control group and combination group, 45 cases for each. For patients in control group, treatment of Pirarubicin postoperative immediately bladder irrigation was provided after transurethral resection of bladder tumors. For patients in combination group, combined treatment of Pirarubicin postoperative immediately bladder irrigation and compound matrine injection were provided after transurethral resection of bladder tumors. T lymphocyte subsets, cytokines, liver and renal functions of patients in each group were detected before and after treatment.Results: No statistical difference showed on T lymphocyte subsets, cytokines, liver and renal functions between two groups of patients with superficial bladder cancer before and after treatment. Compared with prior treatment, CD8+, cytokines (IFN-γ and IL-2), liver function indexes (AST and ALT) and renal function indexes (BUN and Cre) were significantly increased in two groups of patients after treatment, while T lymphocyte subsets (CD3+, CD4+ and CD4+/CD8+) and cytokines (TNF-α, IL-6 and CRP) were significantly decreased. Differences showed statistical significance. After combined treatment given, T lymphocyte subsets (CD3+, CD4+ and CD4+/CD8+) and cytokines (IFN-γ and IL-2) in combination group were significantly higher than in control group after treatment, cytokines (TNF-α, IL-6 and CRP), CD8+, liver function indexes (AST and ALT) and renal function indexes (BUN and Cre) were significantly lower than in control group after treatment. Differences between the two groups showed statistical significance.Conclusion:Combination of Pirarubicin postoperative immediately bladder irrigation and compound matrine injection could enhance immune functions, improve inflammatory reactions and decrease chemotherapeutics toxicities for patients with superficial bladder cancer. It is of great significance on clinical therapy for those patients.
机译:目的:探讨吡柔比星术后立即膀胱冲洗联合复方苦参碱注射液治疗浅表性膀胱癌的机制,为浅表性膀胱癌的临床治疗提供帮助。方法:我院收治的90例浅表性膀胱癌患者选择并随机分为对照组和联合组,每组45例。对于对照组患者,经尿道电切术清除膀胱肿瘤后,应立即进行吡柔比星的术后膀胱冲洗治疗。对于合并组患者,经尿道膀胱肿瘤电切术后,联合应用吡柔比星术后立即进行膀胱冲洗和复方苦参碱注射液。结果:治疗前后两组浅表性膀胱癌患者的T淋巴细胞亚群,细胞因子,肝肾功能均无统计学差异。治疗后。与先前治疗相比,两组患者治疗后CD8 +,细胞因子(IFN-γ和IL-2),肝功能指数(AST和ALT)以及肾功能指数(BUN和Cre)显着增加,而T淋巴细胞亚群(CD3 +,CD4 +和CD4 + / CD8 +)和细胞因子(TNF-α,IL-6和CRP)明显降低。差异显示统计学意义。联合治疗后,联合治疗组的T淋巴细胞亚群(CD3 +,CD4 +和CD4 + / CD8 +)和细胞因子(IFN-γ和IL-2)显着高于对照组,治疗后细胞因子(TNF-α,IL-6)和CRP),CD8 +,肝功能指标(AST和ALT)和肾功能指标(BUN和Cre)均显着低于对照组。两组之间的差异具有统计学意义。结论:吡柔比星术后立即膀胱冲洗联合复方苦参碱注射液可增强浅表膀胱癌患者的免疫功能,改善炎症反应,降低化疗药物的毒性。对于这些患者的临床治疗具有重要意义。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2017年第2期|52-56|共5页
  • 作者单位

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

    Department of Urology, Renmin Hospital of Haimen, Haimen City, Jiangsu Province, 226100 China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号